What is the current stock price of Idorsia Ltd (IDIA.SW)?

The current stock price of Idorsia Ltd is CHF 3.8, reflecting a 6.15% increase from the previous day’s close of CHF 3.58 on the Swiss Exchange. Stock prices can fluctuate based on market conditions, economic factors, and company-specific events.

How is Idorsia Ltd's financial health?

Idorsia Ltd has a P/E ratio of -6.02 and an EPS of -0.62, indicating some financial challenges. However, its revenue per share is CHF 1.07, suggesting a potential for improvement.

What are Idorsia Ltd's strategic collaborations?

Idorsia has collaborations with Janssen Biotech, Hoffman-La Roche, and others, focusing on developing new drugs across various therapeutic areas like CNS, cardiovascular diseases, and cancer immunotherapy.

What is the future outlook for Idorsia Ltd?

Idorsia Ltd’s future outlook depends on successful product developments and market adoption. The biotech sector's inherent volatility means potential high returns versus associated risks.

What are the technical indicators for Idorsia Ltd?

The RSI is at 64.16, and the ADX at 31.5 suggests a strong trend. Bollinger Bands indicate volatility potential, with an upper limit of CHF 3.56 and a lower limit of CHF 2.87.

CH Stocks

Analyzing Idorsia Ltd (IDIA.SW): A Deep Dive into Its Recent Performance and Prospects

ByHuzaifa Zahoor December 8, 2025December 8, 2025

Idorsia Ltd (IDIA.SW), active on the Swiss Exchange, witnessed a significant rise of 6.15% to CHF 3.8, following a period of volatility. The biopharmaceutical firm, specializing in drug development for unmet medical needs, has shown an impressive YTD growth exceeding 217%. Despite its complexities, the healthcare sector offers unique opportunities for high-risk, high-reward investments.